MX2017015373A - COMPOSICIONES Y MíTODOS PARA LA DEGRADACIíN DE PROTEíNAS MAL PLEGADAS. - Google Patents
COMPOSICIONES Y MíTODOS PARA LA DEGRADACIíN DE PROTEíNAS MAL PLEGADAS.Info
- Publication number
- MX2017015373A MX2017015373A MX2017015373A MX2017015373A MX2017015373A MX 2017015373 A MX2017015373 A MX 2017015373A MX 2017015373 A MX2017015373 A MX 2017015373A MX 2017015373 A MX2017015373 A MX 2017015373A MX 2017015373 A MX2017015373 A MX 2017015373A
- Authority
- MX
- Mexico
- Prior art keywords
- compositions
- methods
- misfolded proteins
- degradation
- proteins
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/12—Mucolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5058—Neurological cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10041—Use of virus, viral particle or viral elements as a vector
- C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562168309P | 2015-05-29 | 2015-05-29 | |
| PCT/US2016/034751 WO2016196328A1 (en) | 2015-05-29 | 2016-05-27 | Compositions and methods for degradation of misfolded proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017015373A true MX2017015373A (es) | 2018-07-06 |
Family
ID=57441753
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017015373A MX2017015373A (es) | 2015-05-29 | 2016-05-27 | COMPOSICIONES Y MíTODOS PARA LA DEGRADACIíN DE PROTEíNAS MAL PLEGADAS. |
| MX2024001616A MX2024001616A (es) | 2015-05-29 | 2017-11-29 | Composiciones y metodos para la degradacion de proteinas mal plegadas. |
| MX2021014954A MX2021014954A (es) | 2015-05-29 | 2017-11-29 | Composiciones y metodos para la degradacion de proteinas mal plegadas. |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024001616A MX2024001616A (es) | 2015-05-29 | 2017-11-29 | Composiciones y metodos para la degradacion de proteinas mal plegadas. |
| MX2021014954A MX2021014954A (es) | 2015-05-29 | 2017-11-29 | Composiciones y metodos para la degradacion de proteinas mal plegadas. |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11542500B2 (https=) |
| EP (1) | EP3302706A4 (https=) |
| JP (3) | JP7011467B2 (https=) |
| KR (2) | KR20240108531A (https=) |
| CN (1) | CN108271364A (https=) |
| AU (3) | AU2016271635B2 (https=) |
| BR (1) | BR112017025574A2 (https=) |
| CA (1) | CA2987057A1 (https=) |
| HK (1) | HK1252757A1 (https=) |
| IL (3) | IL255912B2 (https=) |
| MX (3) | MX2017015373A (https=) |
| RU (2) | RU2021134920A (https=) |
| SG (1) | SG10202011833TA (https=) |
| WO (1) | WO2016196328A1 (https=) |
| ZA (1) | ZA201708067B (https=) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201703148TA (en) | 2014-11-05 | 2017-05-30 | Voyager Therapeutics Inc | Aadc polynucleotides for the treatment of parkinson's disease |
| CA3193811A1 (en) | 2014-11-14 | 2016-05-19 | Voyager Therapeutics, Inc. | Compositions and methods of treating amyotrophic lateral sclerosis (als) |
| CN119876138A (zh) | 2014-11-14 | 2025-04-25 | 沃雅戈治疗公司 | 调节性多核苷酸 |
| CA3024448C (en) | 2016-05-18 | 2025-09-09 | Voyager Therapeutics, Inc. | MODULATING POLYNUCLEOTIDES |
| CN110753557B (zh) * | 2017-03-22 | 2024-03-22 | 神济昌华(北京)生物科技有限公司 | Trim72通过泛素化fus蛋白突变体作为als的潜在治疗性靶标 |
| EP3618839A4 (en) | 2017-05-05 | 2021-06-09 | Voyager Therapeutics, Inc. | COMPOSITIONS AND METHODS OF TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) |
| JOP20190269A1 (ar) | 2017-06-15 | 2019-11-20 | Voyager Therapeutics Inc | بولي نوكليوتيدات aadc لعلاج مرض باركنسون |
| CN109609614B (zh) * | 2017-09-30 | 2022-07-15 | 首都医科大学附属北京胸科医院 | 检测trim2、trim4、trim32和/或trim46基因或蛋白产品的用途 |
| WO2019079242A1 (en) | 2017-10-16 | 2019-04-25 | Voyager Therapeutics, Inc. | TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) |
| TW202413649A (zh) | 2017-10-16 | 2024-04-01 | 美商航海家醫療公司 | 肌萎縮性脊髓側索硬化症(als)之治療 |
| CN108018303A (zh) * | 2017-12-20 | 2018-05-11 | 江苏浩欧博生物医药股份有限公司 | 一种人Ro52重组蛋白的制备方法 |
| WO2019175881A1 (en) | 2018-03-14 | 2019-09-19 | Technion Research & Development Foundation Limited | A prognostic biomarker in cancer |
| SG11202011296VA (en) | 2018-05-15 | 2020-12-30 | Voyager Therapeutics Inc | Compositions and methods for the treatment of parkinson's disease |
| US11147815B2 (en) | 2018-08-21 | 2021-10-19 | Synkrino Biotherapeutics, Inc. | Compositions and methods for treating diseases associated with uncontrolled inflammatory responses |
| EP3863642A4 (en) * | 2018-10-09 | 2022-06-29 | The Regents of the University of California | Covalent targeting of e3 ligases |
| WO2020227515A1 (en) * | 2019-05-07 | 2020-11-12 | Voyager Therapeutics, Inc. | Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation |
| CN110302383A (zh) * | 2019-07-29 | 2019-10-08 | 深圳先进技术研究院 | Trim11基因和蛋白靶点以及抑制剂在乳腺癌中的用途 |
| CN110669791B (zh) * | 2019-10-29 | 2020-08-04 | 成都益安博生物技术有限公司 | 一种提高细胞抗体表达量的方法 |
| KR102114880B1 (ko) * | 2020-01-15 | 2020-05-26 | 서울대학교병원 | 코돈 최적화된 TIF1γ 폴리뉴클레오티드를 포함하는 재조합 벡터 및 이의 용도 |
| GB202005876D0 (en) * | 2020-04-22 | 2020-06-03 | Univ Dundee | Protein degradation |
| WO2022165313A1 (en) | 2021-02-01 | 2022-08-04 | Regenxbio Inc. | Gene therapy for neuronal ceroid lipofuscinoses |
| CN113292658B (zh) * | 2021-04-17 | 2023-02-28 | 复旦大学 | 一种融合蛋白及其在靶向降解细胞内蛋白中的应用 |
| CN113651879A (zh) * | 2021-08-18 | 2021-11-16 | 武汉华美生物工程有限公司 | 一种trim21全长蛋白的制备方法及应用 |
| CN117159747B (zh) * | 2023-08-30 | 2024-12-20 | 暨南大学 | 一种亨廷顿舞蹈症的药物及其制备方法 |
| CN118272444A (zh) * | 2024-02-29 | 2024-07-02 | 宜昌市中心人民医院(三峡大学第一临床医学院、三峡大学附属中心人民医院) | 一种慢病毒载体LV-Trim69及其在制备改善心脏衰老药物上的应用 |
| CN120209082B (zh) * | 2025-05-28 | 2025-08-05 | 中南大学 | 一种靶向阻断trim25与brd7蛋白结合的多肽及其应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20010027182A1 (en) * | 1998-05-29 | 2001-10-04 | Huda Y. Zoghbi | Chaperone suppression of ataxin-1 aggregation and altered subcellular proteasome localization imply protein misfilind in sca1 |
| WO2001090342A2 (en) | 2000-05-22 | 2001-11-29 | Johns Hopkins University | Genetic engineering of vascular grafts to resist disease |
| US20040235733A1 (en) * | 2003-02-27 | 2004-11-25 | Steffan Joan S. | Methods and reagents for reducing polyglutamine toxicity |
| US20050215562A1 (en) * | 2003-06-23 | 2005-09-29 | Patrick Tremblay | Methods for treating protein aggregation disorders |
| WO2005081911A2 (en) * | 2004-02-25 | 2005-09-09 | Dana-Farber Cancer Institute, Inc. | METHODS AND COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF HIV INFECTION USING TRIM5α |
| US20140056873A1 (en) | 2004-06-10 | 2014-02-27 | University Of Leicester | Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation |
| WO2006116716A2 (en) * | 2005-04-27 | 2006-11-02 | University Of Florida | Materials and methods for enhanced degradation of mutant proteins associated with human disease |
| EP1870107A1 (en) * | 2006-06-23 | 2007-12-26 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of inducer of promyelocytic leukemia protein (PML) for treating polyglutamine expansion neurodegenerative diseases |
| US7785857B2 (en) | 2006-08-31 | 2010-08-31 | Saint Louis University | Protein C variant |
| CA2749163A1 (en) | 2009-01-14 | 2010-07-22 | The Salk Institute For Biological Studies | Methods for screening and compounds that protect against amyloid diseases |
| EP2826860B1 (en) * | 2010-04-23 | 2018-08-22 | University of Massachusetts | CNS targeting AAV vectors and methods of use thereof |
| GB201012410D0 (en) * | 2010-07-23 | 2010-09-08 | Medical Res Council | Intracellular immunity |
| AU2011295629B2 (en) | 2010-09-01 | 2014-05-01 | Organ Transport Pty Ltd | Perfusion composition |
| CN103127492A (zh) * | 2011-11-23 | 2013-06-05 | 中国科学院上海巴斯德研究所 | 一种抗丙型肝炎病毒的蛋白及其用途 |
| TR201905612T4 (tr) * | 2012-12-05 | 2019-05-21 | Univ Heidelberg Ruprecht Karls | Proteinlerin ve çok değerlikli, hücreye nüfuz eden peptitlerin konjugatları ve bunların kullanımları. |
| US20160136123A1 (en) * | 2013-06-14 | 2016-05-19 | Vojo P. Deretic | Treatment of autophagy-related disorders |
| WO2016054554A1 (en) * | 2014-10-03 | 2016-04-07 | University Of Massachusetts | Heterologous targeting peptide grafted aavs |
-
2016
- 2016-05-27 US US15/577,915 patent/US11542500B2/en active Active
- 2016-05-27 BR BR112017025574-0A patent/BR112017025574A2/en not_active Application Discontinuation
- 2016-05-27 EP EP16804142.4A patent/EP3302706A4/en active Pending
- 2016-05-27 AU AU2016271635A patent/AU2016271635B2/en active Active
- 2016-05-27 CA CA2987057A patent/CA2987057A1/en active Pending
- 2016-05-27 RU RU2021134920A patent/RU2021134920A/ru unknown
- 2016-05-27 IL IL255912A patent/IL255912B2/en unknown
- 2016-05-27 HK HK18112082.4A patent/HK1252757A1/zh unknown
- 2016-05-27 JP JP2017561811A patent/JP7011467B2/ja active Active
- 2016-05-27 SG SG10202011833TA patent/SG10202011833TA/en unknown
- 2016-05-27 WO PCT/US2016/034751 patent/WO2016196328A1/en not_active Ceased
- 2016-05-27 RU RU2017144862A patent/RU2761564C9/ru active
- 2016-05-27 CN CN201680044063.4A patent/CN108271364A/zh active Pending
- 2016-05-27 KR KR1020247021052A patent/KR20240108531A/ko active Pending
- 2016-05-27 IL IL322085A patent/IL322085A/en unknown
- 2016-05-27 MX MX2017015373A patent/MX2017015373A/es unknown
- 2016-05-27 IL IL302965A patent/IL302965B2/en unknown
- 2016-05-27 KR KR1020177037891A patent/KR20180011276A/ko not_active Ceased
-
2017
- 2017-11-28 ZA ZA2017/08067A patent/ZA201708067B/en unknown
- 2017-11-29 MX MX2024001616A patent/MX2024001616A/es unknown
- 2017-11-29 MX MX2021014954A patent/MX2021014954A/es unknown
-
2021
- 2021-09-24 JP JP2021155978A patent/JP2022000459A/ja active Pending
-
2022
- 2022-02-02 AU AU2022200673A patent/AU2022200673B2/en active Active
- 2022-11-21 US US18/057,308 patent/US20230313190A1/en active Pending
-
2024
- 2024-08-15 JP JP2024135688A patent/JP2024161501A/ja active Pending
-
2025
- 2025-09-09 AU AU2025230665A patent/AU2025230665A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2017015373A (es) | COMPOSICIONES Y MíTODOS PARA LA DEGRADACIíN DE PROTEíNAS MAL PLEGADAS. | |
| CY1124663T1 (el) | Αντιιικα παραγωγα ν4-υδροξυκυτιδινης | |
| CL2019002542A1 (es) | Nuevas moléculas de unión a antígeno biespecíficas capaces de unirse específicamente a cd40 y a fap. | |
| JOP20200228A1 (ar) | تركيبات وطرق لخفض تعبير البروتين tau | |
| BR112019012342A2 (pt) | anticorpos il-11 | |
| BR112019012343A2 (pt) | anticorpos il-11ra | |
| CO2018006461A2 (es) | Moléculas de anticuerpo contra april y usos de las mismas | |
| ECSP17070399A (es) | Anticuerpos contra icos | |
| EA202090632A1 (ru) | Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов | |
| EA201892386A1 (ru) | Химерные нейротоксины | |
| MX2019007834A (es) | Composiciones para modular la expresion de c9orf72. | |
| CU20170052A7 (es) | Moléculas de anticuerpo que se unen a pd-l1 | |
| EA201691765A1 (ru) | Молекулы антител против lag-3 и их применения | |
| MX370506B (es) | Método para tratar trastorno de estrés post-traumático. | |
| MX385409B (es) | Proceso para manipular el nivel de contenido de glicano de una glicoproteína. | |
| MX375524B (es) | Anticuerpos anti-axl. | |
| MX376105B (es) | Método para producir l-aminoacidos utilizando una bacteria alcalifílica. | |
| JOP20210010A1 (ar) | بروتينات مخصصة ل baff و b7rp1 وإستخداماتها | |
| MX2018003301A (es) | Inhibidores de pcna. | |
| UY36173A (es) | Metodo de tratamiento de enfermedades relacionadas con el factor inducible por hipoxia | |
| MX2018007468A (es) | Composiciones de colageno 7 y metodos para usar las mismas. | |
| EA201692367A1 (ru) | Сироп от кашля, содержащий амброксола гидрохлорид | |
| DK3898985T3 (da) | Proteinekspression i tandem | |
| BR112016007816A2 (pt) | composições peptídicas inovadoras | |
| MX380683B (es) | Lisobactina para su uso en el tratamiento de la mastitis bovina. |